Regulation of Downstream Targets. Advances in Protein Chemistry and Structural Biology Volume 134

Table of Contents

1. Transcriptional regulatory mechanisms and signaling networks in cancer
Chandrabose Selvaraj, Karthik Raja Ramalingam, Devadasan Velmurugan, and Sanjeev Kumar Singh
2. Identification of dysregulated canonical pathways associated with pathogenesis and progression of Amyotrophic Lateral Sclerosis-An integrated bioinformatics approach
Ankur Datta, S. Udhaya Kumar, Maria D'costa, Anusha Bothe, D. Thirumal Kumar, Hatem Zayed, and C. George Priya Doss
3. Elucidating the mechanism of antimicrobial resistance in Mycobacterium tuberculosis using gene interaction networks
Keerthana G., Karthick Vasudevan, Hrituraj Dey, Tasmia Kausar, S. Udhaya Kumar, D. Thirumal Kumar, Hatem Zayed, and C. George Priya Doss
4. AMPK-like proteins and their function in female reproduction and gynecologic cancer
Claire Baumgartner, Anil Kumar Yadav, and Ilana Chefetz
5. A compilation of bioinformatic approaches to identify novel downstream targets for the detection and prophylaxis of cancer
Mangala Hegde, Sosmitha Girisa, and Ajaikumar B. Kunnumakkara
6. Protein phosphatases and their targets: Comprehending the interactions in plant signaling pathways
Lokesh K. Saini, Malathi Bheri, and Girdhar K. Pandey
7. Calcium decoders and their targets: The holy alliance that regulate cellular responses in stress signaling
Barkha Ravi, Sibaji K. Sanyal, and Girdhar K. Pandey
8. Importin alpha family NAAT/IBB domain: Functions of a pleiotropic long chameleon sequence
Kazuya Jibiki, Takashi S. Kodama, and Noriko Yasuhara
9. AURORA KINASE A and related downstream molecules: A potential network for cancer therapy
Homa Fatma, and Hifzur R. Siddique
10. Emerging role of heat shock proteins in cardiovascular diseases
Joyita Hazra, Anupama Vijayakumar, and Nitish R. Mahapatra
11. Function, structure, evolution, regulation of a potent drug target, arylalkylamine N-acetyltransferase
Lei Zhang, Yu Tang, David J. Merkler, and Qian Han
12. Analysis of signaling cascades from myeloma cells treated with pristimerin
Heba Almaghrbi, Rehab Elkardawy, S. Udhaya Kumar, Shilpa Kuttikrishnan, Taghreed Abunada, Manoj Kumar Kashyap, Aamir Ahmad, Shahab Uddin, C. George Priya Doss, and Hatem Zayed
13. Mixed lineage kinase domain-like pseudokinase: Conventional (necroptosis) and unconventional (necroptosisindependent) functions and features
Tuna Onal, Melike Ozgul-Onal, and Ilana Chefetz

Authors

Rossen Donev Head of Research, MicroPharm Limited, UK. Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.